Role of GLP-1 in Lipid Metabolism and Weight Loss

In the SELECT trial, semaglutide reduced triglycerides by 18.34% and cut the risk of heart attack, stroke, or cardiovascular death by 20% over four years. The weight loss gets most of the attention, but these lipid changes may be just as important for long-term health.

GLP-1 medications like Ozempic, Wegovy, and Mounjaro are prescribed for weight loss in Singapore, and the clinical data shows they do more than suppress appetite. They change how your body processes and stores fat at a metabolic level. Here is what the trial data actually says about lipid effects, and what it means if you are considering GLP-1 treatment.

How GLP-1 medications affect your lipids

GLP-1 receptor agonists work on multiple pathways that influence fat metabolism. Some of these effects happen even in people who lose relatively little weight, which suggests the medications are doing something to lipids directly.

Triglyceride reduction

Elevated triglycerides are one of the most common lipid abnormalities in people with obesity. GLP-1 medications lower triglycerides through two mechanisms: direct effects on the liver (reducing VLDL production, the main carrier of triglycerides in the blood) and indirect effects from weight loss.

The numbers from clinical trials:

Tirzepatide's dual action on both GLP-1 and GIP receptors appears to produce a stronger effect on triglycerides than semaglutide alone.

Cholesterol changes

The cholesterol picture is more nuanced. GLP-1 medications tend to:
- Increase HDL cholesterol (the protective kind). In SELECT, HDL rose by 4.86%.
- Reduce total cholesterol modestly.
- Have a smaller effect on LDL than on triglycerides.

For people whose main lipid problem is high triglycerides with low HDL, which is common in metabolic syndrome, GLP-1 medications address the pattern directly.

Reduced inflammation markers

Chronic low-grade inflammation in fat tissue worsens insulin resistance and cardiovascular risk. GLP-1 medications reduce inflammatory markers like C-reactive protein (CRP). In the SELECT trial, CRP dropped by 39.12% in the semaglutide group, compared to 2.08% with placebo. Researchers found that only 20-60% of the CRP reduction could be explained by weight loss and blood sugar improvements. The rest appears to be a direct anti-inflammatory effect of the medication.

Visceral fat reduction

Not all fat is metabolically equal. Visceral fat, the fat surrounding your organs, produces more inflammatory molecules and is more strongly linked to cardiovascular disease than subcutaneous fat. GLP-1 medications preferentially reduce visceral fat. In the STEP 1 trial, semaglutide reduced visceral fat area by 27.4% over 68 weeks. Epicardial fat (the fat around the heart) decreased by 20% within 12 weeks in a separate controlled study.

This matters because visceral fat is what drives the lipid pattern most associated with obesity: high triglycerides, low HDL, and elevated inflammation.

What the major trials showed

SELECT trial: cardiovascular outcomes

SELECT is the largest cardiovascular outcomes study for a GLP-1 medication to date. It enrolled 17,604 adults with obesity and existing cardiovascular disease (but no diabetes) and followed them for an average of 39.8 months.

Semaglutide 2.4mg weekly produced:
- 20% reduction in major adverse cardiovascular events (heart attack, stroke, or cardiovascular death)
- 10.2% sustained weight loss at 208 weeks (vs 1.5% placebo)
- Triglycerides down 18.34%
- HDL up 4.86%
- CRP down 39.12%
- 52.4% of participants improved their BMI category by week 104

The cardiovascular benefits were seen even in participants who lost less weight, which suggests the lipid and anti-inflammatory effects contribute independently.

SURMOUNT-1: tirzepatide's metabolic effects

The SURMOUNT-1 trial tested tirzepatide in 2,539 adults with obesity but without diabetes. At the 15mg dose over 72 weeks:
- Weight loss: 20.9% (ITT) / 22.5% (efficacy estimand)
- Triglycerides: reduced by ~20-25%
- HDL: increased by 8.0%
- 91.5% of participants with prediabetes returned to normal blood sugar levels

Tirzepatide works on two receptors (GLP-1 and GIP), which appears to produce stronger metabolic improvements than GLP-1 alone.

STEP 1: semaglutide weight and lipid data

The STEP 1 trial enrolled 1,961 adults with overweight or obesity (without diabetes). Semaglutide 2.4mg weekly for 68 weeks produced 14.9% weight loss along with reductions in triglycerides, VLDL cholesterol, and free fatty acids. 86.4% of participants lost more than 5% of their body weight, and 50.5% lost more than 15%.

GLP-1 weight loss timeline and lipid improvements

The lipid changes follow a predictable timeline that mirrors the dose titration schedule.

Months 1-3 (dose titration phase): Appetite suppression starts within the first 1-2 weeks. Weight loss in this period is typically 2-5 kg, with water weight coming off first. Early lipid changes begin as visceral fat starts to decrease. Most gastrointestinal side effects occur during this phase and usually settle within 4-6 weeks.

Months 3-6 (active weight loss): Weight loss accelerates as you reach the maintenance dose. Cholesterol improvements become measurable on blood tests. Triglycerides and CRP typically show clear reductions by month 4-5.

Months 6-12 and beyond: Weight loss peaks around week 65, then stabilises. Lipid improvements are sustained as long as treatment continues. In the SELECT trial, participants maintained a 10.2% weight reduction and sustained lipid improvements at 208 weeks (4 years).

There is a catch, though: these benefits depend on continued treatment. In the STEP 1 extension study, participants who stopped semaglutide regained about two-thirds of their weight within a year, and lipid improvements reversed alongside the weight regain.

For more on what happens when you stop, see our article on maintaining weight after GLP-1 treatment.

Who benefits most from GLP-1 lipid effects

GLP-1 medications are not lipid-lowering drugs in the same category as statins. They are weight loss medications that happen to improve lipid profiles along the way. The people who benefit most from the lipid angle are those with:

• Metabolic syndrome (high triglycerides, low HDL, elevated blood sugar, high blood pressure, large waist circumference). GLP-1 medications address multiple components at once.
• Type 2 diabetes with dyslipidaemia. In the STEP 2 trial, semaglutide produced 9.6% weight loss in participants with T2D, along with improvements in blood sugar control and lipid profiles.
• Elevated cardiovascular risk. The SELECT trial showed a 20% MACE reduction specifically in people with existing cardiovascular disease.
• High triglycerides that respond poorly to statins. Statins primarily lower LDL. GLP-1 medications do more for triglycerides and HDL.

If your main concern is isolated high LDL cholesterol with normal triglycerides and no weight issues, GLP-1 medications are probably not the right tool. Statins remain the first-line treatment for LDL reduction.

Getting GLP-1 treatment in Singapore

GLP-1 medications are available in Singapore as prescription-only medications. You can access them through in-person clinics or through MOH-licensed telehealth services like Trimly.

Medications available:
- Ozempic (semaglutide 0.5-1mg injection, registered for T2D, prescribed off-label for weight loss)
- Wegovy (semaglutide 2.4mg injection, for weight management)
- Rybelsus (oral semaglutide 14mg daily, for T2D, produces more modest weight loss of 3-5%)
- Mounjaro/Zepbound (tirzepatide injection, dual GLP-1/GIP agonist)

Your doctor will recommend a specific medication based on your lipid profile, weight loss goals, and medical history. If you have existing cardiovascular risk factors, the lipid benefits may be an important part of the treatment rationale.

Treatment plans at Trimly range from $350 to $650 per month, covering consultation, medication, delivery, and unlimited follow-ups. Learn more about how Trimly's consultations work or see what doctors assess before prescribing GLP-1.

Frequently asked questions

Does Ozempic lower cholesterol?

Ozempic (semaglutide) has a modest effect on total cholesterol but a stronger effect on triglycerides and HDL. In clinical trials, semaglutide reduced triglycerides by about 18% and increased HDL by about 5%. It is not a cholesterol-lowering medication in the way statins are, but the lipid improvements are a useful secondary benefit for people using it for weight loss.

How long before GLP-1 medications affect my lipid levels?

Most people see measurable changes in triglycerides and inflammatory markers (CRP) by months 3-4, once they reach the maintenance dose and have lost some weight. HDL improvements tend to follow slightly later. Your doctor should check your lipid panel at baseline and again at 3-6 months to track progress.

Can I take GLP-1 medication together with a statin?

Yes. GLP-1 medications and statins work through different mechanisms and can be used together safely. Statins primarily lower LDL cholesterol. GLP-1 medications primarily lower triglycerides and raise HDL. If you have both high LDL and high triglycerides, the combination may address both problems more effectively than either medication alone.

Is GLP-1 treatment available in Singapore?

Yes. GLP-1 medications including Ozempic, Wegovy, and Rybelsus are available in Singapore through prescription. You can get a prescription through an in-person clinic or through an MOH-licensed telehealth service like Trimly, which offers video consultations, medication delivery, and unlimited follow-ups from $350/month.

Key takeaways

GLP-1 medications improve lipid profiles in ways that go beyond what weight loss alone would explain. Triglycerides drop 18-25%, HDL goes up 5-8%, and CRP falls by around 39%. The SELECT trial showed these changes translate into 20% fewer cardiovascular events over four years. If you have obesity alongside lipid problems, these medications tackle both at once. Talk to a doctor to find out whether GLP-1 treatment makes sense for your lipid profile and overall health.